Latest news with #COM902
Yahoo
3 days ago
- Business
- Yahoo
Compugen to Present AI/ML Driven Predictive Computational Research at Upcoming International Scientific Conferences
HOLON, Israel, June 12, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the presentation of AI/ML driven predictive computational research at upcoming international scientific conferences reflecting Compugen's scientific capabilities in understanding complex cancer biology. Poster details: Conference: 2025 Annual Congress of the European Association for Cancer Research, June 16-19 Lisbon, PortugalPoster number: EACR25-3113Title: Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypesPresenting author: Amir Toporik, Computational Discovery, CompugenDate of presentation: June 18, 2025 Conference: International Society for Computational Biology and European Conference on Computational Biology- Annual International Conference on Intelligent Systems for Molecular Biology, July 20-24, 2025, Liverpool, UKPoster number: 947Title: Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanismsPresenting author: Itamar Borukhov, Ph.D., Computational Discovery, Compugen Posters will be available in the publications section of Compugen's website, following presentation. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. Company contact: Yvonne Naughton, of Investor Relations and Corporate CommunicationsEmail: ir@ +1 (628) 241-0071 View original content: SOURCE Compugen Ltd.
Yahoo
05-03-2025
- Business
- Yahoo
Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Cash Balance: Approximately $103.3 million as of December 31, 2024. Revenue: $1.5 million for Q4 2024; $27.9 million for the full year 2024. R&D Expenses: $5.9 million for Q4 2024; $24.8 million for the full year 2024. G&A Expenses: $2.2 million for Q4 2024; $9.4 million for the full year 2024. Net Loss: $6.1 million for Q4 2024; $14.2 million for the full year 2024. Cash Runway: Expected to last into 2027. Warning! GuruFocus has detected 3 Warning Signs with CGEN. Release Date: March 04, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Compugen Ltd (NASDAQ:CGEN) presented encouraging data for COM701, showing durable responses and good tolerability in platinum-resistant ovarian cancer patients. The company plans to advance COM701 as a maintenance treatment for platinum-sensitive ovarian cancer, targeting a less competitive landscape. AstraZeneca's initiation of seven Phase 3 trials with rilvegostomig, derived from Compugen's COM902, represents a significant potential revenue source. Compugen Ltd (NASDAQ:CGEN) received a $30 million milestone payment from Gilead for GS-0321's FDA IND clearance, validating their discovery and development capabilities. The company maintains a solid financial position with a cash runway expected to last into 2027, supporting their strategic priorities and clinical advancements. Compugen Ltd (NASDAQ:CGEN) reported a net loss of approximately $14.2 million for the year ended December 31, 2024. Revenues for 2024 decreased compared to 2023, with $27.9 million reported versus $33.5 million in the previous year. The TIGIT antibody class faced skepticism due to several setbacks and program discontinuations in 2024. The ovarian cancer study is exploratory and not powered to detect significant improvements, which may limit its impact. There is uncertainty regarding the timeline and outcomes of AstraZeneca's Phase 3 trials, which could affect future revenue streams. Q: Can you confirm whether rilvegostomig will be included in AstraZeneca's Phase 3 study design for the B7-H4 DCPSAM? A: Anat Cohen-Dayag, President and CEO, stated that they cannot comment on anything not publicly disclosed by AstraZeneca. However, they are pleased with the progress of the seven pivotal trials AstraZeneca has initiated, which include testing rilvegostomig in various combinations. Q: Can we expect any near-term data from AstraZeneca that could clarify the contribution to efficacy for the TIGIT part? A: Anat Cohen-Dayag mentioned that AstraZeneca plans to present data in 2025 from the combination of rilvegostomig with ADCs. Previous data from rilvegostomig in non-small cell lung cancer and gastric cancer have shown promising efficacy and safety profiles. Q: What is the design of the ovarian study, and how is it powered to show PFS hazard ratio? A: Michelle Mahler, Chief Medical Officer, explained that the study is an exploratory Phase 1B study, not powered for a full pivotal trial. It uses Bayesian statistics to evaluate the probability of a more than three-month improvement in progression-free survival (PFS) compared to placebo. Q: Is there interest in evaluating GS-0321 in hematologic malignancies, possibly in combination with rituximab? A: Eran Ophir, VP of Research, stated that while hematological applications are interesting, the current focus is on solid tumors where they have observed unique activity in the tumor microenvironment. Q: What triggers the interim analysis in the platinum-sensitive ovarian cancer study, and is there a predefined futility threshold? A: Michelle Mahler explained that the interim analysis is triggered by a combination of event rate and follow-up duration. There is a futility boundary, and Bayesian statistics will be used to assess the probability of a three-month improvement in PFS. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
